These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 21630267)

  • 1. Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors.
    Pesonen S; Diaconu I; Cerullo V; Escutenaire S; Raki M; Kangasniemi L; Nokisalmi P; Dotti G; Guse K; Laasonen L; Partanen K; Karli E; Haavisto E; Oksanen M; Karioja-Kallio A; Hannuksela P; Holm SL; Kauppinen S; Joensuu T; Kanerva A; Hemminki A
    Int J Cancer; 2012 Apr; 130(8):1937-47. PubMed ID: 21630267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF.
    Koski A; Kangasniemi L; Escutenaire S; Pesonen S; Cerullo V; Diaconu I; Nokisalmi P; Raki M; Rajecki M; Guse K; Ranki T; Oksanen M; Holm SL; Haavisto E; Karioja-Kallio A; Laasonen L; Partanen K; Ugolini M; Helminen A; Karli E; Hannuksela P; Pesonen S; Joensuu T; Kanerva A; Hemminki A
    Mol Ther; 2010 Oct; 18(10):1874-84. PubMed ID: 20664527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans.
    Bramante S; Koski A; Kipar A; Diaconu I; Liikanen I; Hemminki O; Vassilev L; Parviainen S; Cerullo V; Pesonen SK; Oksanen M; Heiskanen R; Rouvinen-Lagerström N; Merisalo-Soikkeli M; Hakonen T; Joensuu T; Kanerva A; Pesonen S; Hemminki A
    Int J Cancer; 2014 Aug; 135(3):720-30. PubMed ID: 24374597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients.
    Cerullo V; Pesonen S; Diaconu I; Escutenaire S; Arstila PT; Ugolini M; Nokisalmi P; Raki M; Laasonen L; Särkioja M; Rajecki M; Kangasniemi L; Guse K; Helminen A; Ahtiainen L; Ristimäki A; Räisänen-Sokolowski A; Haavisto E; Oksanen M; Karli E; Karioja-Kallio A; Holm SL; Kouri M; Joensuu T; Kanerva A; Hemminki A
    Cancer Res; 2010 Jun; 70(11):4297-309. PubMed ID: 20484030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus.
    Kanerva A; Nokisalmi P; Diaconu I; Koski A; Cerullo V; Liikanen I; Tähtinen S; Oksanen M; Heiskanen R; Pesonen S; Joensuu T; Alanko T; Partanen K; Laasonen L; Kairemo K; Pesonen S; Kangasniemi L; Hemminki A
    Clin Cancer Res; 2013 May; 19(10):2734-44. PubMed ID: 23493351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: Results in vitro, in rodents and in humans.
    Bramante S; Kaufmann JK; Veckman V; Liikanen I; Nettelbeck DM; Hemminki O; Vassilev L; Cerullo V; Oksanen M; Heiskanen R; Joensuu T; Kanerva A; Pesonen S; Matikainen S; Vähä-Koskela M; Koski A; Hemminki A
    Int J Cancer; 2015 Oct; 137(7):1775-83. PubMed ID: 25821063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors.
    Pesonen S; Nokisalmi P; Escutenaire S; Särkioja M; Raki M; Cerullo V; Kangasniemi L; Laasonen L; Ribacka C; Guse K; Haavisto E; Oksanen M; Rajecki M; Helminen A; Ristimäki A; Karioja-Kallio A; Karli E; Kantola T; Bauerschmitz G; Kanerva A; Joensuu T; Hemminki A
    Gene Ther; 2010 Jul; 17(7):892-904. PubMed ID: 20237509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Multi Targeting Conditionally Replicating Adenovirus Displays Enhanced Oncolysis while Maintaining Expression of Immunotherapeutic Agents.
    Dobbins GC; Ugai H; Curiel DT; Gillespie GY
    PLoS One; 2015; 10(12):e0145272. PubMed ID: 26689910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-specific oncolytic adenoviruses expressing granulocyte macrophage colony-stimulating factor or anti-CTLA4 antibody for the treatment of cancers.
    Du T; Shi G; Li YM; Zhang JF; Tian HW; Wei YQ; Deng H; Yu DC
    Cancer Gene Ther; 2014 Aug; 21(8):340-8. PubMed ID: 25034886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapy.
    Hemminki O; Parviainen S; Juhila J; Turkki R; Linder N; Lundin J; Kankainen M; Ristimäki A; Koski A; Liikanen I; Oksanen M; Nettelbeck DM; Kairemo K; Partanen K; Joensuu T; Kanerva A; Hemminki A
    Oncotarget; 2015 Feb; 6(6):4467-81. PubMed ID: 25714011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers.
    Wakayama M; Abei M; Kawashima R; Seo E; Fukuda K; Ugai H; Murata T; Tanaka N; Hyodo I; Hamada H; Yokoyama KK
    Clin Cancer Res; 2007 May; 13(10):3043-50. PubMed ID: 17505007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity.
    Santos JM; Heiniö C; Cervera-Carrascon V; Quixabeira DCA; Siurala M; Havunen R; Butzow R; Zafar S; de Gruijl T; Lassus H; Kanerva A; Hemminki A
    J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31940588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Oncolytic Adenovirus Encoding Decorin and Granulocyte Macrophage Colony Stimulating Factor Inhibits Tumor Growth in a Colorectal Tumor Model by Targeting Pro-Tumorigenic Signals and via Immune Activation.
    Liu Z; Yang Y; Zhang X; Wang H; Xu W; Wang H; Xiao F; Bai Z; Yao H; Ma X; Jin L; Wu C; Seth P; Zhang Z; Wang L
    Hum Gene Ther; 2017 Aug; 28(8):667-680. PubMed ID: 28530155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Case-control estimation of the impact of oncolytic adenovirus on the survival of patients with refractory solid tumors.
    Kanerva A; Koski A; Liikanen I; Oksanen M; Joensuu T; Hemminki O; Palmgren J; Hemminki K; Hemminki A
    Mol Ther; 2015 Feb; 23(2):321-9. PubMed ID: 25381801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of chemotherapy resistant ovarian cancer with a MDR1 targeted oncolytic adenovirus.
    Rein DT; Volkmer A; Beyer IM; Curiel DT; Janni W; Dragoi A; Hess AP; Maass N; Baldus SE; Bauerschmitz G; Breidenbach M
    Gynecol Oncol; 2011 Oct; 123(1):138-46. PubMed ID: 21741695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid tumors.
    Nokisalmi P; Pesonen S; Escutenaire S; Särkioja M; Raki M; Cerullo V; Laasonen L; Alemany R; Rojas J; Cascallo M; Guse K; Rajecki M; Kangasniemi L; Haavisto E; Karioja-Kallio A; Hannuksela P; Oksanen M; Kanerva A; Joensuu T; Ahtiainen L; Hemminki A
    Clin Cancer Res; 2010 Jun; 16(11):3035-43. PubMed ID: 20501623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conditionally replicative adenovirus with tropism expanded towards integrins inhibits osteosarcoma tumor growth in vitro and in vivo.
    Witlox AM; Van Beusechem VW; Molenaar B; Bras H; Schaap GR; Alemany R; Curiel DT; Pinedo HM; Wuisman PI; Gerritsen WR
    Clin Cancer Res; 2004 Jan; 10(1 Pt 1):61-7. PubMed ID: 14734452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modification of the early gene enhancer-promoter improves the oncolytic potency of adenovirus 11.
    Wong HH; Jiang G; Gangeswaran R; Wang P; Wang J; Yuan M; Wang H; Bhakta V; Müller H; Lemoine NR; Wang Y
    Mol Ther; 2012 Feb; 20(2):306-16. PubMed ID: 22086234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined fiber modifications both to target α(v)β(6) and detarget the coxsackievirus-adenovirus receptor improve virus toxicity profiles in vivo but fail to improve antitumoral efficacy relative to adenovirus serotype 5.
    Coughlan L; Vallath S; Gros A; Giménez-Alejandre M; Van Rooijen N; Thomas GJ; Baker AH; Cascalló M; Alemany R; Hart IR
    Hum Gene Ther; 2012 Sep; 23(9):960-79. PubMed ID: 22708837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer.
    Hemminki O; Diaconu I; Cerullo V; Pesonen SK; Kanerva A; Joensuu T; Kairemo K; Laasonen L; Partanen K; Kangasniemi L; Lieber A; Pesonen S; Hemminki A
    Mol Ther; 2012 Sep; 20(9):1821-30. PubMed ID: 22871667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.